INTRODUCTION: Current rapid- and long-acting insulin analogs cannot maintain their individual pharmacokinetic profile when they are co-formulated. IDegAsp , a novel soluble combination was developed with rapid-acting insulin aspart and a new-generation ultra-long-acting insulin, insulin degludec and was anticipated to offer clinical advantage over available premixed insulin suspensions. AREAS COVERED: We reviewed published data regarding pharmacological characters, clinical efficacy, safety, and tolerability of IDegAsp. Literature was searched through the electronic medical databases (PubMed, EMBASE, and Web of Knowledge) up to June 2012. EXPERT OPINION: Preliminary clinical data indicate that IDegAsp is a safe, well-tolerated insulin combination and provides a similar overall glycemic control to current insulin preparations with a reduced risk of hypoglycemia. IDegAsp might be a promising treatment option for patients with type 2 diabetes who need to improve control of postprandial glucose excursions and fasting glucose levels.